<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04732221</url>
  </required_header>
  <id_info>
    <org_study_id>5475-007</org_study_id>
    <secondary_id>2020-001108-40</secondary_id>
    <secondary_id>MK-5475-007</secondary_id>
    <nct_id>NCT04732221</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)</brief_title>
  <official_title>A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-part (Phase 2/Phase 3) study of MK-5475, an inhaled soluble guanylate cyclase&#xD;
      stimulator, in participants with pulmonary arterial hypertension (PAH).&#xD;
&#xD;
      The first part (Phase 2) will assess three different doses of MK-5475 compared to placebo;&#xD;
      the treatment dose with the best efficacy and safety profile will be selected for use in the&#xD;
      second part (Phase 3) of the study. The primary hypothesis of Phase 2 is that at least one&#xD;
      MK-5475 dose group is superior to placebo in reducing pulmonary vascular resistance (PVR)&#xD;
      from baseline at week 12.&#xD;
&#xD;
      The purpose of the second part (Phase 3) of the study is to confirm the efficacy, safety, and&#xD;
      tolerability of MK-5475 at the selected dose compared to placebo during a 12 week base period&#xD;
      followed by an extension period of up to 5 years. The primary hypothesis of Phase 3 is that&#xD;
      MK-5475 is superior to placebo in increasing 6-minute walk distance (6MWD) from baseline at&#xD;
      week 12.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2021</start_date>
  <completion_date type="Anticipated">October 29, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A total of approximately 450 participants will be randomized in this operationally seamless adaptive Phase 2/3 study. Phase 2 of the study will randomize approximately 164 participants into 4 arms, and Phase 3 of the study will randomize approximately 286 participants into 2 arms.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 2 Cohort: Change from Baseline in Pulmonary Vascular Resistance (PVR) at 12 Weeks</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
    <description>PVR is assessed by right heart catheterization (RHC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 3 Cohort: Change from Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
    <description>6MWD is assessed using the 6-minute walk test (6MWT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Cohort: Change from Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
    <description>6MWD is assessed using the 6-minute walk test (6MWT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Cohort: Change from Baseline in Mean Right Arterial Pressure (mRAP) at 12 Weeks</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
    <description>mRAP is assessed by right heart catheterization (RHC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Cohort: Change from Baseline in Cardiac Index (CI) at 12 weeks</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
    <description>Cardiac index is assessed by right heart catheterization (RHC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Cohort: Change from Baseline in Stroke Volume Index (SVI) at 12 weeks</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
    <description>SVI is assessed by right heart catheterization (RHC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3 Cohort: Change from Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks</measure>
    <time_frame>At baseline and 24 weeks</time_frame>
    <description>6MWD is assessed using the 6-minute walk test (6MWT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3 Cohort: Change from Baseline in World Health Organization Functional Class (WHO-FC) at 12 Weeks</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
    <description>Participants are assigned one of four WHO-FC, dependent on limits of physical activity. As WHO-FC increases from I to IV, limits of physical activity increase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Cohort: Number of Participants Who Experience an Adverse Event</measure>
    <time_frame>Up to 14 weeks</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Cohort: Number of Participants Who Discontinue Study Drug Due to an Adverse Event</measure>
    <time_frame>Up to 14 weeks</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3 Cohort: Number of Participants who Experience an Adverse Event</measure>
    <time_frame>Up to approximately 5.5 years</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3 Cohort: Number of Participants who Discontinue Study Drug Due to an Adverse Event</measure>
    <time_frame>Up to approximately 5.5 years</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Phase 2 Cohort MK-5475 380 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive MK-5475 380 µg via oral inhalation once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Cohort MK-5475 100 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive MK-5475 100 µg via oral inhalation once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Cohort MK-5475 32 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive MK-5475 32 µg via oral inhalation once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Cohort Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo via oral inhalation once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3 Cohort MK-5475</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive one of 3 MK-5475 doses (380, 100 or 32 µg) to be selected at end of the Phase 2 Cohort, administered via oral inhalation once daily for 12-week base period and up to 60 months in the extension period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3 Cohort Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo via oral inhalation once daily for 12 week base period and up to 60 months in the extension period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-5475</intervention_name>
    <description>MK-5475 (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation</description>
    <arm_group_label>Phase 2 Cohort MK-5475 100 µg</arm_group_label>
    <arm_group_label>Phase 2 Cohort MK-5475 32 µg</arm_group_label>
    <arm_group_label>Phase 2 Cohort MK-5475 380 µg</arm_group_label>
    <arm_group_label>Phase 3 Cohort MK-5475</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-5475</intervention_name>
    <description>Placebo administered as dry powder inhalation</description>
    <arm_group_label>Phase 2 Cohort Placebo</arm_group_label>
    <arm_group_label>Phase 3 Cohort Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pulmonary arterial hypertension (PAH) in one of the following groups:&#xD;
&#xD;
               -  Idiopathic PAH&#xD;
&#xD;
               -  Heritable PAH&#xD;
&#xD;
               -  Drug and toxin-induced PAH&#xD;
&#xD;
               -  PAH associated with connective tissue disease, HIV infection, or congenital heart&#xD;
                  disease.&#xD;
&#xD;
          -  Diagnosis of PAH documented by right heart catheterization (RHC).&#xD;
&#xD;
          -  Eligibility RHC meeting all of the following criteria:&#xD;
&#xD;
               -  Mean pulmonary artery pressure (mPAP) ≥25 mmHg&#xD;
&#xD;
               -  Pulmonary vascular resistance (PVR) of ≥3 Wood units&#xD;
&#xD;
               -  Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic&#xD;
                  pressure (LVEDP) ≤15 mmHg.&#xD;
&#xD;
          -  World Health Organization functional class (WHO-FC) symptoms between Class II and IV.&#xD;
&#xD;
          -  Two 6-Minute walk distance (6MWD) measurements between 150 and 450 meters, one at&#xD;
             screening and one at randomization.&#xD;
&#xD;
          -  Stable concomitant background PAH-specific therapy.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18.5 kg/m² and 40 kg/m² .&#xD;
&#xD;
          -  Agree to be abstinent from heterosexual intercourse or use contraception during the&#xD;
             intervention period and for at least 14 days after the last dose of study&#xD;
             intervention.&#xD;
&#xD;
          -  Female participants may not be pregnant or breastfeeding.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Group 2 to 5 pulmonary hypertension.&#xD;
&#xD;
          -  PAH in one of the following groups:&#xD;
&#xD;
               -  Long term responders to calcium channel blockers&#xD;
&#xD;
               -  Overt features of venous/capillary involvement&#xD;
&#xD;
          -  Evidence of more-than-mild obstructive lung disease.&#xD;
&#xD;
          -  Evidence of more-than-mild parenchymal lung disease.&#xD;
&#xD;
          -  Evidence of untreated obstructive sleep apnea (OSA).&#xD;
&#xD;
          -  Evidence or history of left heart disease, including any of the following:&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) ≤45%&#xD;
&#xD;
               -  Moderate or severe left-sided valvular disease (aortic or mitral valve stenosis&#xD;
                  or regurgitation)&#xD;
&#xD;
               -  Significant left ventricular diastolic dysfunction on echocardiographic&#xD;
                  evaluation&#xD;
&#xD;
          -  Presence of 3 or more of the following risk factors for heart failure with preserved&#xD;
             ejection fraction: BMI&gt;30 kg/m², essential systemic hypertension, diabetes mellitus of&#xD;
             any type, or coronary artery disease.&#xD;
&#xD;
          -  Oxygen saturation measured by pulse oximetry (SpO₂) &lt;90%, despite supplemental oxygen&#xD;
             therapy.&#xD;
&#xD;
          -  Chronic renal insufficiency (eGFR &lt;30 mL/min)&#xD;
&#xD;
          -  Chronic liver disease (i.e., Child-Pugh B or C), portal hypertension, cirrhosis, or&#xD;
             significant hepatic laboratory abnormalities.&#xD;
&#xD;
          -  Current smoker or currently uses electronic cigarettes (vapes).&#xD;
&#xD;
          -  History of cancer, except: nonmelanomatous skin carcinoma or carcinoma in situ of the&#xD;
             cervix or other malignancies which have been successfully treated, with appropriate&#xD;
             follow up, and unlikely to recur for the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Davis Medical Center ( Site 0002)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>916-734-1554</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado - Denver ( Site 0003)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-848-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of North Colorado - Banner Health ( Site 0013)</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>80631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>970-810-0900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital ( Site 0025)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-444-8830</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando ( Site 0040)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-303-7556</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital [Indianapolis, IN] ( Site 0045)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>317-962-9700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center ( Site 0038)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>913-588-4022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky ( Site 0006)</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>859-323-0295</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Pulmonary Associates ( Site 0048)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>502-587-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland ( Site 0032)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-328-6885</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center ( Site 0041)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>402-559-7585</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Unit at Eastowne Medical Office Building ( Site 0019)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>984-974-2966</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AnMed Health ( Site 0033)</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>864-512-8734</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Research Institute ( Site 0036)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-441-7182</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital ( Site 0014)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>757-388-5480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral ( Site 0138)</name>
      <address>
        <city>Pilar</city>
        <state>Buenos Aires</state>
        <zip>B1629ODT</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+54 230 448-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Cardiovascular de Rosario ( Site 0128)</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DSR</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+54 93416164246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Privado Universitario de Córdoba ( Site 0137)</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+54 351 468-8200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Macquarie University ( Site 0180)</name>
      <address>
        <city>Macquarie University</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61294226000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Cardiovascular Colombiano Clínica Santa María ( Site 0154)</name>
      <address>
        <city>Medellín</city>
        <state>Antioquia</state>
        <zip>050034</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573136859942</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Ignacio ( Site 0152)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110231</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5712882284</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Brest - Hopital Cavale Blanche ( Site 0254)</name>
      <address>
        <city>Brest</city>
        <state>Finistere</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33298223333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hopital Larrey ( Site 0258)</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556795679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Coeur Poumon - CHRU de Lille ( Site 0252)</name>
      <address>
        <city>Lille Cedex</city>
        <state>Nord-Pas-de-Calais</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33320445721</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU - Hopital de Bicetre ( Site 0251)</name>
      <address>
        <city>Le Kremlin-Bicetre</city>
        <state>Val-de-Marne</state>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33145212121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Giessen und Marburg GmbH ( Site 0279)</name>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4964198560</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover ( Site 0284)</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49 511 532 3548</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Dresden ( Site 0283)</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49 3513177238</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig ( Site 0285)</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493419716250</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center ( Site 0330)</name>
      <address>
        <city>Beer Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97286403832</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0335)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97250206171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center ( Site 0331)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972506865209</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 0327)</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239377221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Naples Federico II ( Site 0308)</name>
      <address>
        <city>Naples</city>
        <state>Campania</state>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390817462242</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino IRCCS ( Site 0306)</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390258002299</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital ( Site 0201)</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+64274677583</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greenlane Clinical Centre ( Site 0203)</name>
      <address>
        <city>Auckland</city>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6493074949x21646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Szpital im. Dr Alfreda Sokolowskiego w Walbrzychu ( Site 0351)</name>
      <address>
        <city>Walbrzych</city>
        <state>Dolnoslaskie</state>
        <zip>58-309</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48746489622</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie ( Site 0352)</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>601366148</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute Complex Problems Cardiovascular Disease ( Site 0403)</name>
      <address>
        <city>Kemerovo</city>
        <state>Kemerovskaya Oblast</state>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+73842341902</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 0510)</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>903123055000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akdeniz Uni.Tip Fakultesi Saglik Uygulama ve Arastirma Merkezi ( Site 0508)</name>
      <address>
        <city>Antalya</city>
        <zip>07059</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902422496770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eskisehir Osmangazi Uni. Tip Fakultesi Hastanesi ( Site 0506)</name>
      <address>
        <city>Eskisehir</city>
        <zip>26040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905332337849</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Uni. Kardiyoloji Enstitusu ( Site 0502)</name>
      <address>
        <city>Istanbul</city>
        <zip>34096</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322860797</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Istanbul Tip Fakultesi ( Site 0509)</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322831726</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 0501)</name>
      <address>
        <city>Istanbul</city>
        <zip>34899</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902166254545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi Hastanesi ( Site 0504)</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905324123489</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University Faculty of Medicine ( Site 0505)</name>
      <address>
        <city>Izmir</city>
        <zip>35330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902324122210</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

